TG Therapeutics Claimed Company
TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. read more
HR or Marketing? Claim Your Free Employer Account
TG Therapeutics CEO & Leadership Team Ratings
Michael S. Weiss and the TG Therapeutics leadership team are scored a C+ by 18 employees placing it in the Top 50% of companies sized 201-500 Employees on Comparably. The Leadership score includes details about how employees evaluate their executive team, CEO and manager.
Women have higher ratings for their leadership team compared to Men. Hispanic or Latino employees have the most favorable ratings for their leadership team compared to Caucasian employees.
Based on 77 ratings, the Leadership score of 69/100 combines employee feedback on their CEO (76/100), Manager (71/100), and Executive Team (67/100).
Michael S. Weiss TG Therapeutics CEO Rating
Top 15% Compared to other companies of similar size on ComparablyA-
76 / 100
Michael S. Weiss the CEO of TG Therapeutics received an average score of 76 from TG Therapeutics employees.Female employees at TG Therapeutics rate the CEO the highest.
Hispanic or Latino employees at TG Therapeutics rate the CEO the highest.
TG Therapeutics Manager Rating
Top 40% Compared to other companies of similar size on ComparablyB-
71 / 100
TG Therapeutics Executive Team Rating
Top 50% Compared to other companies of similar size on ComparablyC+
67 / 100
×